Friday, March 22, 2019 1:46:40 AM
BUY
INITIATION OF COVERAGE
.Financial Summary
Changes Previous
Current
Amarin Corporation PLC
AMRN – NASDAQ
March 21, 2019 Biotechnology Takeout Or Bust? Initiating Coverage With a Buy Rating and a
$27 Target Price
Summary
We believe Vascepa's REDUCE-IT study results are impressive and based on our physician survey, will most certainly lead to robust growth, likely above management's 2019 guidance. With that said, our call here does run counter to the prevailing sentiment that AMRN will be acquired in the near term and believe the outcome of an advisory committee discussing the REDUCE-IT results and controversies around them will be needed before a takeout can occur. Our diligence with regulatory experts get us comfortable with an FDA approval for a Vascepa label expansion to include reduction in CV risk based on the REDUCE-IT results in early 2020, which should effectively increase its addressable market size by a factor of 20. From a valuation perspective, we use a blended methodology given the takeout premium in the stock and arrive at a $27 target price.
Key Points
There is no doubt the REDUCE-IT data are already having a positive impact on Vascepa scripts and based on our physician survey and discussion with physicians at the American College of Cardiology (ACC) meeting earlier this week, we think 2019 guidance is probably beatable. REDUCE- IT demonstrated an outstanding ~25% relative risk reduction on 5-part MACE in patients with high triglycerides with controlled LDL-C. Already, IQVIA scripts have seen robust growth since the REDUCE-IT study results were published in the NEJM in January 2019 and we believe that momentum will continue. Our survey of current and non-prescribers of Vascepa suggests: (1) among current prescribers (n=63) we surveyed (PCPs, Endos and Cardiologists), ~95% expect to increase utilization in the next 12 months particularly in patients with triglycerides of >150mg/dL - <500mg/dL where they expect ~10-25% of their patients to be put on therapy in 2019, ahead of sNDA approval; (2) after the REDUCE-IT results, ~80% of physicians who currently do not prescribe Vascepa (n=39) said they plan to prescribe, with PCPs the most bullish on its usage. Our 2019 forecast of ~$370 million is ahead of management's guidance of ~$350 million and consensus estimates of ~$362 million. We forecast ~$2.5 billion in stand alone US peak sales in 2029.
Controversies centering on the use of mineral oil as a placebo in the REDUCE-IT study remain a key question which is unlikely to be settled until a potential advisory committee in early 2020, but we think it ultimately goes AMRN's way. Our discussions with a former FDA Medical Officer from the Division of Metabolism and Endocrinology (pg. 42) and former panel member from Vascepa's ANCHOR advisory committee (pg. 43) suggest: (1) the 10% increase in LDL-C and the meaningful rise in hsCRP in the control group in REDUCE-IT will certainly be a case for the FDA to convene an advisory committee; (2) the FDA will likely use a statistical approach to determine the mineral oil effect, which, when looking at the linear relationship between LDL-C and CV risk, is likely modest and unlikely to make REDUCE-IT a failed study given how robust Vascepa's benefit was. We come away with the belief that there is a better chance than not Vascepa's soon to be filed sNDA will be approved. With that said, the resolution of this controversy may not occur until 2020, which could disappoint investors hoping for a near-term takeout since would-be acquirers may prefer to await the outcome. If no advisory committee is scheduled, we'd view this as a positive sign.
We try to take a thoughtful approach using a blended valuation methodology given the takeout premium in the stock. On a stand alone basis using a probability-weighted DCF (~50% of valuation) between 2019-2037, we arrive at a $17 valuation. Recall, AMRN has already settled with TEVA (NC, $16.86) for generic entry in August 2029 for both its 1g and 0.5g presentations. We believe this valuation serves as a floor for the stock and think on takeout (~50% of valuation), AMRN could sell for ~6x EV/peak sales translating to a $37 target price, which assumes an acquirer can achieve greater peak sales than AMRN standalone.
Rating Buy
Target Price FY19E EPS FY20E EPS FY19E Revenue FY20E Revenue
Price ( 03/20/19 ): 52-Week Range: Market Cap.(mm): Shr.O/S-Diluted (mm): Avg Daily Vol (3 Mo): Net Cash/Share: Dividend / Yield:
Cash (mm):
Revenue 2018A Q1 $44.0 Q2 $53.0 Q3 $55.0 Q4 $77.0 FY (Dec) $229.0A
EPS 2018A Q1 $(0.07) Q2 $(0.10) Q3 $(0.06) Q4 $(0.09) EPS $(0.33)A
Price Performance
— — — —
$27.00
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM